Palatin Technologies Inc PTN

Healthcare Biotechnology

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.

NYSEAM:PTN - Post by User

Palatin Technologies Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jun 12, 2024 4:30pm

35 Views

Post# 36085681

Palatin Initiates Phase 2 Clinical Study of Bremelanotide fo

JUST IN: $PTN Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...PTN - Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages